TLSINasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31Also trades as TLSIW

TriSalus Life Sciences, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026

$3.53−0.10 (-2.75%)

Close on Oct 19, 2026

Market cap: $205.79M
P/E (TTM): –
Dividend yield: –

TriSalus Life Sciences, Inc. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Revenue	45	29	19	12	–
Cost of Revenue	6.97	4.10	2.61	2.26	–
Gross Profit	38	25	16	10	–
Research & Development	15	18	30	21	–
Selling, General & Admin	50	44	41	25	–
Selling & Marketing	29	26	17	13	–
General & Administrative	21	18	24	12	3.04
Advertising Expenses	1.40	0.50	1.30	2.20	–
Operating Income	-27	-36	-54	-36	-3.04
Interest Expense	5.54	3.09	0.02	0.00	–
Interest & Investment Income	0.56	0.40	0.43	0.18	0.06
Other Non-Operating Income	-0.46	-0.31	-0.38	-0.42	7.81
Gain (Loss) on Sale of Assets	-0.12	-0.02	-0.04	-0.31	–
Pretax Income	-39	-30	-59	-47	4.77
Income Tax Expense	0.01	0.01	0.01	0.01	0
Net Income incl. Noncontrolling Interests	–	–	–	5.54	4.77
Net Income	-39	-30	-59	-47	4.77
Preferred Dividends	0	3.19	1.26	0	–
Net Income to Common	-70	-33	-64	-50	–
EPS (Basic)(per share)	-1.84	-1.31	-6.77	-161.55	–
EPS (Diluted)(per share)	-1.84	-1.31	-6.77	-161.55	–
Shares Outstanding (Basic, Weighted)(shares)	38	25	9.40	0.31	–
Shares Outstanding (Diluted, Weighted)(shares)	38	25	9.40	0.31	–
EBITDA	-26	-35	-54	-36	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 85.8%
Operating margin: -67.7%
Net margin: -62.6%
Return on equity, FY2025: 131.3%

Financial strength

Current ratio: 5.35
Debt to equity: 5.05
Debt to assets: 52.9%
Cash to current liabilities: 414.3%

Valuation

P/E ratio: –
Price to sales: 4.57
Price to book: 31.42
Dividend yield: –